Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacists improve outcomes but often can’t bill for it, making billing parity key to growing services.
|Articles|December 1, 2004
Formularies shift quickly as Vioxx drops off the market
The Sept. 30 Voluntary Recall of Vioxx (rofecoxib) by Merck is just another in a long list of headline-making news for the industry. The action was based on the results of a three-year, randomized double-blind trial that indicated that after taking Vioxx for 18 months, patients had twice the risk of heart attack compared with a placebo.
Advertisement
Advertisement
Related to this article
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacy should be treated as a clinical service line, not just a 340B financial workhorse.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicaid can't opt out of gene therapies, so planning matters more, says Katelyn Meyer, Pharm.D. | AMCP Nexus 2026
2
How common is atopic dermatitis in the US? Not nearly as common as other research has shown, according to this study
3
5 things you should know about the midterms and healthcare
4
Lower fitness tied to persistent fatty liver disease in teen boys with obesity
5